Literature DB >> 12161585

Response to Ronald M Perkin and David B Resnik: the agony of trying to match sanctity of life and patient-centred medical care.

Helga Kuhse1.   

Abstract

Perkin and Resnik advocate the use of muscle relaxants to prevent the "agony of agonal respiration" arguing that this is compatible with the principle of double effect. The proposed regime will kill patients as certainly as smothering them would. This may lead some people to reject the argument as an abuse of the principle of double effect. I take a different view. In the absence of an adequate theory of intention, the principle of double effect cannot distinguish between the intentional and merely foreseen termination of life, and cannot rule out end-of-life decisions that are often regarded as impermissible. What Perkin and Resnik are in effect saying is that there are times when physicians have good reasons to end a patient's life--deliberately and intentionally--for the patient's (and the family's) sake. Why not say so--instead of going through the agony of trying to match sanctity of life and patient-centred medical care?

Entities:  

Keywords:  Analytical Approach; Death and Euthanasia

Mesh:

Substances:

Year:  2002        PMID: 12161585      PMCID: PMC1733620          DOI: 10.1136/jme.28.4.270

Source DB:  PubMed          Journal:  J Med Ethics        ISSN: 0306-6800            Impact factor:   2.903


  2 in total

1.  Dutch pediatricians' views on the use of neuromuscular blockers for dying neonates: a qualitative study.

Authors:  K ten Cate; S van de Vathorst
Journal:  J Perinatol       Date:  2015-01-22       Impact factor: 2.521

Review 2.  Ethical reflections on end-of-life signs and symptoms in the intensive care setting: a place for neuromuscular blockers?

Authors:  Cédric Daubin; Lise Haddad; Dominique Folscheid; Alexandre Boyer; Ludivine Chalumeau-Lemoine; Olivier Guisset; Philippe Hubert; Jérôme Pillot; René Robert; Didier Dreyfuss
Journal:  Ann Intensive Care       Date:  2014-07-08       Impact factor: 6.925

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.